2.15
+0.02(+0.94%)
Currency In USD
| Previous Close | 2.13 |
| Open | 2.15 |
| Day High | 2.23 |
| Day Low | 2.13 |
| 52-Week High | 13.07 |
| 52-Week Low | 1.29 |
| Volume | 338,753 |
| Average Volume | 752,361 |
| Market Cap | 127.65M |
| PE | -0.71 |
| EPS | -3 |
| Moving Average 50 Days | 1.84 |
| Moving Average 200 Days | 2.49 |
| Change | 0.02 |
If you invested $1000 in Biomea Fusion, Inc. (BMEA) since IPO date, it would be worth $118.82 as of October 03, 2025 at a share price of $2.21. Whereas If you bought $1000 worth of Biomea Fusion, Inc. (BMEA) shares 3 years ago, it would be worth $219.25 as of October 03, 2025 at a share price of $2.21.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Oct 01, 2025 11:00 AM GMT
SAN CARLOS, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on September 24, 2025, the compensation committee of
Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update
GlobeNewswire Inc.
Sep 16, 2025 11:00 AM GMT
In a rodent model of T2D, icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and body weight reduction with preservation of lean mass, outperforming the group given semaglutide alone.U.S. Food and Drug Administrati
Biomea Fusion Appoints Julianne Averill to its Board of Directors
GlobeNewswire Inc.
Jul 24, 2025 11:00 AM GMT
SAN CARLOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the appointment of Julianne Averill to i